ICAM1 and familial isolated congenital asplenia: These findings suggest that targeting ICAM1‐related pathways could optimize stent treatment strategies, emphasizing the importance of ICAM1 regulation in reducing the risk of watershed infarction and improving therapeutic outcomes in ICAS management.